7,406.50

+4.50

+0.06%

51,604.00

+219.00

+0.43%

26,991.75

-93.50

-0.35%

Russell 2000 Futures

2,769.30

+8.80

+0.32%

4.8590

+0.0220

+0.45%

25.64

-2.54

-9.01%

4,081.80

+6.90

+0.17%

74,778.08

-919.86

-1.22%

Crude Oil Dec 26

90.47

-0.36

-0.40%

US Private Equity

10,772.76

+11.83

+0.11%

Frankfurt - Delayed Quote EUR

Ultragenyx Pharmaceutical Inc. (UP0.F)

13.54 -1.57 (-10.42%)

At close: November 6 at 8:04:40 AM GMT+1

Loading Chart for UP0.F

Chart Range Bar

Interval:

In partnership with ChartIQ

Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down

Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down

Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA)

Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA)

Ultragenyx Pharmaceutical Inc (RARE) Q3 2026 Earnings Call Highlights: Gene Therapy Launches, ...

Ultragenyx Pharmaceutical Inc (RARE) Q3 2026 Earnings Call Highlights: Gene Therapy Launches, ...

Ultragenyx Pharmaceutical (RARE) Stock Looks Fairly Valued After Upcoming FDA Decisions

Ultragenyx Pharmaceutical (RARE) Stock Looks Fairly Valued After Upcoming FDA Decisions

Ultragenyx (RARE) Q3 2026 Earnings Call Transcript

Ultragenyx (RARE) Q3 2026 Earnings Call Transcript

Ultragenyx Pharmaceutical Inc. Q3 2026 Earnings Call Summary

Ultragenyx Pharmaceutical Inc. Q3 2026 Earnings Call Summary

Gene Therapy Launches Could Be A Game Changer For Ultragenyx Stock (RARE)

Gene Therapy Launches Could Be A Game Changer For Ultragenyx Stock (RARE)

Ultragenyx Pharmaceutical (RARE) Recasts The Story After FDA Approvals As Valuation Debate Builds

Ultragenyx Pharmaceutical (RARE) Recasts The Story After FDA Approvals As Valuation Debate Builds

What Ultragenyx Pharmaceutical (RARE) Said on Its Q3 Earnings Call

What Ultragenyx Pharmaceutical (RARE) Said on Its Q3 Earnings Call

Ultragenyx (RARE) Reports Q3 Loss, Lags Revenue Estimates

Ultragenyx (RARE) Reports Q3 Loss, Lags Revenue Estimates

Compared to Estimates, Ultragenyx (RARE) Q3 Earnings: A Look at Key Metrics

Compared to Estimates, Ultragenyx (RARE) Q3 Earnings: A Look at Key Metrics

Mobilize your Website

View Site in Mobile | Classic

Share by: